Joanna Opalinska trained as clinical hematologist/oncologist in Poland and in Germany. Joanna developed further skills in basic and translational research in the area of normal and malignant hematopoiesis and modulation of gene expression by antisense technology at the University of Pennsylvania, and at the Children’s Hospital of Philadelphia. Joanna made the transition to industry in 2010 when she has joined GSK and led the early development of Belantamab, anti BCMA-ADC in multiple myeloma. After achieving POC Joanna has built a team and continued to led the clinical development, which resulted in US and EU approvals of Belantamab. Under her leadership the program received an orphan drug designation, breakthrough and PRIME designation.